clinical trial · NCT00603980
Staccato Alprazolam Abuse Liability
Nova Pneuma Inc.·phase1·completed·n = 31
Abuse Liability of Staccato AlprazolamInhaled placebo + oral placeboInhaled alprazolam 0.5 mgInhaled alprazolam 1 mgInhaled alprazolam 2 mgOral alprazolam 1 mgOral alprazolam 2 mgOral alprazolam 4 mOral alprazolam 2 mg qualifying session
brief summary
Compare the abuse liabilities of Staccato Alprazolam, oral immediate-release alprazolam, and Staccato Placebo.
started
Jan 1, 2008
primary completion
Jan 1, 2009
completion
Jan 1, 2009
last updated
Apr 22, 2026
detailed description
The Phase 1 clinical study compared the abuse liabilities of Staccato Alprazolam, oral immediate-release alprazolam, and Staccato Placebo in 14 subjects with a history of sedative abuse. Subjects who met the inclusion/exclusion criteria received 2 mg of oral alprazolam and matching placebo over 2 sessions. Those who demonstrated greater liking for alprazolam versus placebo were eligible to participate in the study.
official title
Abuse Liability Study of Staccato® Alprazolam for Inhalation in Subjects With Histories of Sedative Abuse
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol